Skip to main content

Table 1 Participant characteristics by country

From: The International development of PROQOL-HCV: An instrument to assess the health-related quality of life of patients treated for Hepatitis C virus

Variables

Australia n = 20

Brazil n = 20

France n = 30

Total N = 70

Demographic factors

 Male Sex

17 (85.0)

6 (30.0)

21 (70.0)

44 (62.9)

 Age

48.7 (6.0)

51.8 (9.4)

50.45 (9.7)

50.3 (8.5)

 Weight (kg)

83.0 (19.9)

66.8 (15.4)

70.5 (13.4)

73.0 (17.1)

 Married/partner

5 (25.0)

11 (55.0)

17 (56.7)

33 (47.1)

 Ethnicity Caucasian

18 (90.0)

12 (60.0)

23 (82.1)

53 (75.7)

 Living alone

7 (35.0)

2 (10.0)

9 (30.0)

18 (25.7)

 Living with children

4 (20)

10 (50.0)

14 (46.6)

25 (35.7)

 Education ≥ university

3 (15.0)

4 (20.0)

7 (23.3)

14 (20.0)

 Employmenta

12 (60.0)

6 (30.0)

20 (68.9)

48 (69.6)

 Current smoker

12 (60.0)

7 (35.0)

15 (50.0)

34 (48.6)

 Alcohol last month

15 (75.0)

5 (25.0)

13 (44.8)

33 (47.8)

 Past history of Injecting drugs

17 (85.0)

3 (15.8)

14 (48.3)

34 (50.0)

Treatmentb

 Past history

5 (26.3)

2 (10.0)

17 (58.6)

24 (35.3)

 Current

14 (70.0)

15 (75.0)

13c (46.4)

42 (61.8)

 Pill burden (total number)

8.1 (6.3)

8.2 (4.8)

9.0 (5.4)

8.5 (5.4)

 Antidepressant drugs

7 (35.0)

12 (60.0)

5 (16.7)

24 (34.3)

 Antianxiety drugs

5 (20.0)

4 (20.0)

4 (13.3)

13 (18.6)

 Sedative drugs

4 (20.0)

0 (0.0)

5 (17.9)

9 (13.4)

Clinical factors

 Time since diagnosis (years)

5.0 (13.8)

3.5 (4.5)

8.0 (10.3)

5.0 (10.0)

 HIV-Coinfection

5 (29.4)

5 (27.8)

4 (26.8)

14 (28.0)

 Depression, self-reported (past month)

11 (55.0)

10 (50.0)

12 (41.4)

33 (47.8)

 Symptoms (total number)

12.0 (7.0)

15.0 (13.5)

12.5 (6.0)

13.0 (7.0)

  1. aInclusive of full time and part time work; bBoth interferon alpha and pegylated in combination with ribavirin; c8 patients (32 %) receiving directly acting antiviral drugs
  2. Data are summarised as count (percentage) for categorical variables, and mean (SD) for numerical variables